GLP-1 News & Analysis
Weekly pricing updates, FDA alerts, and expert analysis on the fast-moving GLP-1 landscape.
Ozempic vs Wegovy 2026: Same Molecule, Different Label — Which One Should You Take? (Cost, Dose, Insurance)
Ozempic and Wegovy are the exact same active molecule (semaglutide) from the exact same manufacturer (Novo Nordisk). The differences come down to FDA indication (T2D vs obesity), max dose (2.0 mg vs 2.4 mg), and how insurance treats them. If you have Type 2 diabetes, Ozempic is the right path — $25/mo via Savings Card. If you don't have T2D, Ozempic is off-label and won't be covered; Wegovy is the correct prescription — $25/mo with Savings Card if you qualify on BMI. Cash retail: Ozempic $998/mo, Wegovy $1,349/mo. Compounded: $99/mo via Embody, $146/mo via Yucca, $199/mo via TrimRx. Here's the full head-to-head and the cheapest legitimate path for each.
Wegovy Weight Loss: How Much Will You Actually Lose? Real Week-by-Week Results, Trial Data vs Real World (June 2026)
In the STEP-1 trial, the average patient lost 14.9% of body weight on Wegovy at 68 weeks. STEP-5 showed 15.2% at two years. But real-world data — including a 50,000-patient JAMA Internal Medicine study — shows real-world loss is closer to 6-8% on average, mostly because patients stop early. Here's the realistic week-by-week curve, the four factors that make you lose more (or less) than average, and the cheapest legitimate paths if Wegovy's price tag is the reason you'd quit early.
Mounjaro vs Ozempic 2026: Which T2D GLP-1 Wins for Weight Loss, A1C, and Cost? (Head-to-Head Comparison)
Mounjaro (tirzepatide) and Ozempic (semaglutide) are both FDA-approved only for Type 2 diabetes — but they're the two most-prescribed GLP-1s, on-label and off-label for weight loss. In the SURMOUNT-5 head-to-head trial, tirzepatide produced 20.2% body weight loss vs 13.7% for semaglutide. But Ozempic has 8+ years of cardiovascular and kidney outcome data. Both savings cards drop you to $25/month with insurance — and compounded versions of either start at $99/month. Here's the head-to-head by clinical fit, cost, and cheapest legitimate path.
How to Get Wegovy Covered by Insurance in 2026: Prior Authorization Playbook, Denial Codes, and Appeal Letter Template
Roughly 40% of Wegovy prior authorization requests are denied on first submission — and most denials are reversible. Here's exactly what insurers require (BMI ≥30, or ≥27 with one of 6 comorbidities), what to bring to your visit, the four documentation gaps that trigger 80% of denials, how to win a peer-to-peer review, a copy-paste appeal letter template, and the 4 cheaper paths if your plan refuses to cover it.
Ozempic for PCOS: Does It Work? Cost, Dosing, and the 4 Cheaper Compounded Paths When Insurance Says No (June 2026)
GLP-1s like Ozempic and Wegovy aren't FDA-approved for PCOS — but they directly target the insulin resistance that drives PCOS weight gain, irregular cycles, and acne. The catch: without a Type 2 diabetes or obesity ICD-10 code, insurance almost always denies coverage. Cash-pay brand Ozempic runs $998/month. Here are the four legitimate cheaper paths for PCOS patients in June 2026, the trial data behind GLP-1 for PCOS, and the dose-conversion logic if you're stacking with metformin.
Tirzepatide vs Semaglutide: Which GLP-1 Molecule Wins in 2026? (Cost, Weight Loss, Side Effects Compared)
Tirzepatide (Mounjaro, Zepbound, compounded) drives 22.5% body weight loss in trials vs 15% for semaglutide (Ozempic, Wegovy, compounded). But semaglutide has 7+ years of real-world data, broader insurance coverage, and an oral pill option (Rybelsus). Here's the head-to-head on mechanism, efficacy, side effects, and the cheapest verified path for each — by your situation.
Mounjaro for Weight Loss: How It Works, What It Costs Off-Label, and the 3 Cheaper Paths in June 2026
Mounjaro (tirzepatide) is FDA-approved only for Type 2 diabetes — but it's the same active molecule as Zepbound, which is approved for weight loss. If you're paying $1,069/month cash-pay for off-label Mounjaro, there are three legitimate cheaper paths: get a prediabetes diagnosis to unlock the $25 Savings Card, switch to brand Zepbound, or move to compounded tirzepatide at $99-$249/month. Here's the decision tree.
Is Compounded Semaglutide Getting Banned? What the FDA's 503B Proposal Actually Means — And Where You Can Still Buy It (June 2026)
The FDA has proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — the comment period closes June 29, 2026. If finalized, large-scale outsourcing facilities lose their compounding pathway. But 503A patient-specific pharmacies operate under separate rules, and that's where the market is already moving. Here's what's actually banned, what isn't, the questions to ask your provider this week, and which programs are positioned to keep shipping.
Medicare GLP-1 Bridge Program: Do You Qualify for $50/Month — And What to Do If You Don't (July 2026)
Medicare's $50/month GLP-1 Bridge Program launches July 1, 2026, covering Wegovy, Zepbound, and Foundayo. But the eligibility tiers are stricter than most headlines suggest: BMI ≥35, or ≥30 with heart failure/hypertension/CKD, or ≥27 with prediabetes or prior heart attack/stroke. Here's exactly who qualifies, how enrollment actually works (your doctor submits — you can't), and the cheapest legitimate options if you're in the gap.
How to Get Wegovy Cheaper in June 2026: 7 Real Paths from $25 to $1,349/Month (Before the July 1 Medicare Launch)
Wegovy lists at $1,349/month but most patients never pay that. The seven legitimate cheaper paths in June 2026: $25/mo Wegovy Savings Card (insured), $50/mo Medicare bridge (starts July 1), $25/mo Ozempic Savings Card (if T2D), $249/mo NovoCare direct, $99-249/mo compounded semaglutide, $149/mo oral Foundayo, and $1,349/mo retail. Here's exactly which path fits your situation — and the timing trick if you're 24 days from Medicare launch.
How to Switch from Ozempic to Compounded Semaglutide (June 2026): 6 Programs, Dose Conversion, Step-by-Step
If you're paying $700-$1,000/month for Ozempic and your insurance dropped semaglutide coverage, compounded semaglutide is the same active molecule for $99-$199/month from a licensed US telehealth pharmacy. Here's the exact dose conversion, the 6 programs that ship reliably in June 2026, and the timing trick to switch without losing weight-loss progress.
Cheapest Compounded Semaglutide Online: 7 Verified Programs Ranked (June 2026)
Compounded semaglutide — same active molecule as Ozempic and Wegovy — is available from licensed US telehealth providers starting at $99/month. We compared June 2026 pricing, pharmacy partners, LegitScript status, shipping speed, and what happens if FDA removes semaglutide from the shortage list. Here's where to actually buy it.
How to Get Zepbound Cheaper in 2026: 6 Real Paths from $25 to $349/Month
Zepbound lists at $1,089/month but real-world cost ranges from $25 (Lilly Savings Card) to $349 (LillyDirect vials) to $99 (compounded tirzepatide). Here's every legitimate path to get Zepbound's molecule cheaper in May 2026 — including the Mounjaro route most patients miss.
Cheapest Compounded Tirzepatide Online: 6 Verified Programs Compared (May 2026)
Compounded tirzepatide — the same active ingredient in Zepbound and Mounjaro — is available from licensed US telehealth providers starting at $99/month. We verified pricing, pharmacy partners, credentialing, and shipping speed for the 6 cheapest legitimate programs in May 2026.
Ozempic Long-Term Safety: What 90,000-Patient Heart & Kidney Studies Reveal (May 2026)
New May 2026 research: GLP-1s cut major cardiovascular events 13-26%, sharply lower kidney disease and sleep apnea risk — but stopping for just 6 months erases the protection. Here's what 90,000+ patients reveal about staying on Ozempic long-term, and the cheapest providers if cost is the reason you'd quit.
Best Wegovy Alternatives in 2026 (By Cost, Effectiveness, Insurance)
Wegovy works, but it's not the only path. In 2026 the legitimate alternatives range from more potent ($349/mo Zepbound vials) to cheaper ($149/mo Foundayo pill, $99/mo compounded semaglutide) to insurance-friendlier (Mounjaro if you have diabetes). Here's the head-to-head comparison and which alternative fits which patient.
Does Zepbound Cause Hair Loss? What the Data Shows (2026)
Yes — about 5.7% of patients on the highest Zepbound dose report hair shedding in clinical trials, with real-world telehealth rates running 8-12%. It's almost always temporary telogen effluvium driven by rapid weight loss, not the drug itself. Here's how to prevent it, treat it, and which providers actually screen for it.
How to Get Mounjaro for $25 a Month (2026 Savings Card Guide)
Eli Lilly's Mounjaro Savings Card drops your copay to $25/month — but only for commercially insured patients with a type 2 diabetes diagnosis. Here's exactly who qualifies, how to enroll, what to do if your insurance refuses prior auth, and the legitimate paths if $25 isn't available to you.
How Long Do Zepbound Side Effects Last? (2026 Timeline by Side Effect)
Most Zepbound side effects start within 24-72 hours of an injection and resolve in 1-2 weeks at each new dose level. Nausea peaks first; fatigue and constipation linger longer. Here's the timeline by symptom — and when persistent side effects mean it's time to adjust your dose.
Is Zepbound the Same as Mounjaro? Yes — Here's What That Means for Your Cost (2026)
Same molecule (tirzepatide), same manufacturer (Eli Lilly), same dose strengths — different FDA label. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Here's how that affects your cost, insurance coverage, and how to access the cheapest legitimate path in 2026.
Can You Stay on a Low Dose of Wegovy? Maintenance Dose Guide (2026)
Yes — and most patients who hit their goal weight should. The FDA label says 2.4 mg, but real-world clinical practice routinely uses 1.0–1.7 mg (or lower) for maintenance. Here's what works, what insurance will pay for, and which providers will actually customize your dose.
Is Zepbound Better Than Wegovy? Head-to-Head 2026 (Cost, Results, Side Effects)
For most patients, yes. Zepbound delivers ~20% mean weight loss vs Wegovy's ~14% in the head-to-head SURMOUNT-5 trial. But cost, side effects, and the new $149/month oral pills flip the answer for some patients. Here's the 2026 breakdown.
Ozempic & GLP-1 Hair Loss: What 84,000 Patients Reveal (May 2026)
A 2026 meta-analysis of 84,000 GLP-1 users found 3.4× higher hair-loss risk vs non-users. Here's why it happens, who it hits hardest, what stops it, and which providers help.
GLP-1 Microdosing: Does It Work? Cost, Providers & What the Science Says (2026)
GLP-1 microdosing — taking 0.05-0.125mg/week instead of standard 0.25-2.4mg — is trending. Here's what clinicians actually say, who offers it, and what it costs.
"Gut Reset" May Lock In GLP-1 Weight Loss After Quitting (New Study)
A new sham-controlled trial shows a minimally invasive gut procedure helped patients keep 80% of their GLP-1 weight loss after stopping tirzepatide. Here's what it means.
Quitting and Restarting Your GLP-1? What It Does to Your Muscles (2026)
Fewer than 1 in 4 patients stay on a GLP-1 after one year. Up to 40% of weight lost is muscle. Each stop-restart cycle makes it worse. Here's what the research says — and how to avoid the trap.
24 Million Americans Just Lost GLP-1 Coverage — Here's What Actually Happened
NPR reports 12 million lost Zepbound coverage and 12 million lost Wegovy coverage in the past year. CVS Caremark, BCBS Massachusetts, and Harvard Pilgrim all pulled back. Here's the full list — and what you can do right now.
Insurance Dropped Your GLP-1? 5 Cheapest Options (2026)
41 million Americans lost commercial GLP-1 coverage in 2026. CVS Caremark dropped Zepbound, BCBS restricted Wegovy. Here are the cheapest ways to keep your medication without insurance.
Your Genes May Predict How Much Weight You'll Lose on GLP-1s (New Study)
A massive 23andMe study published in Nature found genetic variants that predict GLP-1 weight loss (6-20%) and nausea risk (5-78%). Here's what it means for choosing your medication.
Hims Drops Compounded Semaglutide: What the Novo Nordisk Deal Means for You
Hims partnered with Novo Nordisk, stopped advertising compounded GLP-1s, and now offers FDA-approved Wegovy starting at $149/month. Here's what changes for patients.
Foundayo Ships Today: How to Get Eli Lilly's GLP-1 Pill for $149/Month
LillyDirect began shipping Foundayo on April 6, 2026. Here's exactly how to order, what it costs with and without insurance, and how it compares to every other GLP-1 option.
CMS Balance Model: How Medicare's New GLP-1 Pilot Works (April 2026)
CMS's new Balance Model launches July 2026 as Medicare's first value-based GLP-1 coverage pilot. Here's what Part D patients need to know about eligibility and costs.
GLP-1 Price War 2026: Foundayo $25, Wegovy $249, Compounded $99 — Every Option Ranked
Foundayo at $25/mo with insurance ($149 self-pay), Wegovy subscription $249/mo, compounded tirzepatide from $99, Zepbound vials $349, Medicare Bridge $50 starting July. Updated May 2026 with every legitimate 2026 GLP-1 option ranked by total monthly cost.
FDA Approves Foundayo: The GLP-1 Pill You Take With Food (April 2026)
Eli Lilly's oral weight loss pill got the fastest FDA approval since 2002 on April 1, 2026. Here's how Foundayo compares to oral Wegovy at $149/month.
GLP-1 Pill War: What Orforglipron Means for You (April 2026)
Eli Lilly's oral GLP-1 pill gets its FDA decision April 10. Novo Nordisk just launched Wegovy subscriptions at $249/month. Here's what's happening now.
Medicare GLP-1 Bridge Program: 5 Things to Know Before July 2026
The $50/month Medicare GLP-1 Bridge launches July 1, 2026. Here are 5 things Part D enrollees must prepare now to lock in Wegovy, Zepbound, or Foundayo.
Oral Wegovy at 3 Months: What Early Users Report: 2026 Guide
Three months after the December 2025 launch, here's what real oral semaglutide patients say about weight loss, side effects, and the fasting requirement.
FDA Warns 12 More GLP-1 Compounders (March 2026 Update)
The FDA's March 2026 enforcement wave adds 12 new compounding pharmacies to the warning list, bringing the total past 40 since late 2025. Here's who was flagged.
GLP-1 Price Check: Cheapest Programs This Month (March 2026)
We tracked pricing across 15+ GLP-1 telehealth providers in March 2026. Here's who lowered prices, who raised them, and which compounded plan is cheapest now.
Orforglipron FDA Decision April 10: What It Means (April 2026)
Eli Lilly's oral non-peptide GLP-1 orforglipron faces its FDA PDUFA date April 10, 2026. Here's how this pill could reshape the weight loss landscape.
Stay Informed
We publish new analysis every week covering FDA decisions, provider pricing changes, and clinical trial results.